Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10 mai 2024 17h40 HE
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
09 mai 2024 16h25 HE
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
09 mai 2024 16h05 HE
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
09 mai 2024 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations
09 mai 2024 08h05 HE
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB:KBLB) BAM-1 spider silk spring production trials exceed expectations and Implementing Next Phase of Its Recombinant Spider Silk Plan
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 08h00 HE
|
Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h45 HE
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...